REHOVOT, Israel -- November 16, 1999 -- Weizmann Institute scientists are testing new vanadium compounds that may alleviate the suffering of type II diabetic patients.
Diabetic patients suffer from a metabolic disorder in which the insulin hormone responsible for allowing the passage of energy rich nutrients from the bloodstream into the body¹s cells does not function properly or at all. Diabetes afflicts 15 million Americans, and 90 percent of these cases are classified as type II diabetes, commonly refered to as Adult Onset diabetes. Type I diabetes is caused by a shortage of insulin production from cells in the pancreas.
Since type II diabetes is the result mainly of resistance or insensitivity of cells to insulin activity, one approach to treating this type of diabetes is to find a new chemical that will serve as a viable alternative to insulin and that will not be affected by problems of insulin resistance or insensitivity. Weizmann Institute scientists have recently made significant progress in this area, which may lead to the development of a treatment that will considerably improve the quality of life of those suffering from this disorder.
Some two decades ago, Prof. Yoram Shechter of the Weizmann Institute's Biological Chemistry Department was one of the first scientists to discover that vanadium, a metallic trace element, mimics most of the metabolic effects of insulin in tissue studies. When given to diabetic rodents, vanadium corrects many metabolic defects associated with diabetes, in which insulin is lacking or is not functioning properly.
Since that discovery, scientists at the Institute and elsewhere have conducted intensive studies aimed at utilizing vanadium in the treatment of diabetes, as an artificial substitute for insulin. Unlike insulin, vanadium need not be injected directly into the bloodstream, but can be taken in the form of pills. Moreover, because vanadium's mechanism of action is different from that of insulin, it is particularly valuable in the treatment of cases in which insulin is ineffective.
The use of vanadium as a substitute for insulin, however, has been stymied until now, by the fact that vanadium, like many other metal ions, is toxic in the high concentrations that must be used to make it effective. The goal of vanadium-related research in diabetes has been to develop vanadium-based compounds that are less toxic and, if possible, have greater antidiabetic potency than vanadium itself.
Now, a team of Weizmann Institute scientists including Prof. Yoram Shechter, Prof. Mati Fridkin of the Organic Chemistry Department and graduate student Itzhak Goldwaser have managed to achieve just that. After checking hundreds of chemicals, they have found one family of amino acid analogues that, when forming a complex with vanadium, are three to four times more effective than vanadium alone in mimicking the effects of insulin.
In a study reported in the current issue of the Journal of Biological Chemistry, the Institute scientists showed that the new compounds patented through Yeda Research and Development Co. Ltd., which deals with the commercialization of the Institute's research are effective in regulating glucose levels in diabetic laboratory animals while given in small amounts. These substances are being developed for clinical use by a start- up company, LAPID Pharmaceuticals Ltd., created recently by Pamot Venture Capital Fund and Yeda. Further animal studies must be conducted to show whether the compounds are appropriate for application in humans.
Prof. Shechter holds the Charles H. Hollenberg Chair of Diabetes and Metabolic Research, and Prof. Fridkin, the Lester B. Pearson Chair of Protein Research.
The Weizmann Institute of Science, in Rehovot, Israel, is one of the world¹s foremost centers of scientific research and graduate study. Its 2,500 scientists, students, technicians and engineers pursue basic research in the quest for knowledge and the enhancement of the human condition. New ways of fighting disease and hunger, protecting the environment, and harnessing alternative sources of energy are high priorities.
The above story is based on materials provided by Weizmann Institute. Note: Materials may be edited for content and length.
Cite This Page: